MC2 Therapeutics’ Post

I am proud to share exciting news from this week’s 42nd Annual J.P. Morgan Healthcare Conference, where Moderna announced business updates and progress on our pipeline of transformative mRNA medicines. Through more than a decade of progress and investment in science, Moderna has led the way in establishing the field of mRNA medicine. We have demonstrated the potential for clinical benefit in multiple infectious disease vaccines, oncology, and rare genetic diseases. Based on these clinical successes, we have advanced a broad and diverse pipeline. In 2023, SARS-CoV-2 continued to evolve. With the end of the global public health emergency, our business has adapted to a more predictable, seasonal endemic market. With this shift, we resized our manufacturing footprint and supply base accordingly, which took significant effort. We enter 2024 with 45 therapeutic and vaccine programs, nine of which are in late-stage development.   I look forward to working closely with our teams in the new year to serve even more patient needs faster, utilizing the full capacity of our mRNA platform.      #Moderna #mRNA #HealthSecurity #JPMHC24

Are you relying on biomarker data to verify clinical strategies during drug development or clinical trials? If so, you need ultra-sensitive immune biomarker detection and reliable, reproducible data to help you bring therapeutics to the market. With OmniVUE™, researchers can gather data on project-relevant biomarkers by combining up to any eight of our pre-optimized, validated biomarkers in customizable panels. Our patented InSituPlex® technology generates reliable data using a fast, easy workflow for rapid results that keep projects moving forward. Learn how biomarker assays with a high dynamic range and high reproducibility can help to advance therapeutic development. https://hubs.ly/Q02dpsQm0 #SpatialBiology #Immunology #ImmunoOncology #Biomarkers #PrecisionMedicine #ImmuneProfiling

BenevolentAI announces that AstraZeneca has added a novel target for systemic lupus erythematosus (SLE) to its discovery portfolio through its collaboration with BenevolentAI. Second target to be selected this year from the extended collaboration with AstraZeneca, highlighting continued positive progress in the field of target identification Read More: https://lnkd.in/dGm6a2s8 “Following our recent success in the area of heart failure, I’m delighted that AstraZeneca has selected a novel target for SLE to enter its portfolio. The continued, fruitful efforts of our two companies working in collaboration will help bring potential new therapeutic options to lupus patients, whose quality of life is often severely limited by the disease.” Said Dr Anne Phelan, Chief Scientific Officer of BenevolentAI “Our aim is to lead in lupus by continuing to discover and develop novel treatments that push the efficacy ceiling for patients, allowing more people to achieve remission. By combining our immunology disease area expertise and BenevolentAI’s AI-driven discovery platform, we are increasing our ability to identify new targets based on patient insights, complementing our portfolio of potential treatments for this debilitating disease.” Said Prof Maria Belvisi, SVP and Head of Research and Early Development Respiratory and Immunology at AstraZeneca. #mededgemea #benevolentai #AstraZeneca #pharmacollaboration #DrugDiscovery #aiinhealthcare #medicalresearch #lupus #autoimmunedisease #innovativemedicine #healthtech

Our CEO John Montana spoke with BioWorld News following the announcement of our official company launch and €75 million (US$81 million) Series A financing to advance neutralizing antibodies targeting proinflammatory molecules that drive inflammatory and fibrotic diseases. In the interview John outlines how the funding will be used over the next three years to drive phase IIa data generation across three indications.   ➡️CAL-101, targeting S100A4, is currently in a Phase Ib trial, with results anticipated in the first half of this year. Future plans include Phase IIa proof-of-concept (PoC) studies addressing fibrotic and chronic inflammatory diseases. ➡️CAL-102, targeting oxidised phospholipids (OxPL), is progressing through preclinical development for myocardial infarction induced reperfusion injury, with Phase I development slated for 2025. The funding will propel its progression to generate Phase IIa clinical PoC data in a comparable timeframe to the CAL101 clinical readouts. ➡️CAL-103 will also progress to a Phase Ib biomarker data readout in an inflammatory indication by mid 2026. Read the full interview here: https://rb.gy/pyapsv #Biotech #Biopharma #Immunology #Clinical #Innovation

We're thrilled to highlight groundbreaking research from Chiara Mancino, PhD with members of the Houston Methodist Academic Institute and Baylor College of Medicine on mRNA-based therapeutic vaccines for Chagas disease (CD). These researchers have explored the feasibility of developing an mRNA-based CD vaccine targeting two key T. cruzi vaccine antigens. Their findings reveal promising therapeutic benefits, including reductions in parasite burdens and cardiac inflammation, particularly with the mRNA encoding Tc24 and Tc24 in combination with ASP-2. This study underscores the potential of mRNA-based vaccines as a therapeutic option for CD, paving the way for novel treatment approaches in combating this parasitic disease. Click the link below to access the full article! https://lnkd.in/eG5Z-e2W #biotech #research #drugdelivery #lipidnanoparticle #mrna #vaccines

What’s the benefit of using Teiko's CLIA-validated 42-marker pan-immune PBMC panel for your clinical trials? Our panel is ideal for deep immune profiling of clinical PBMC samples, offering analysis of up to 840 immune subsets and states. With this depth of profiling you’re able to validate mechanisms of action, confirm pre-clinical results, and explore changes to the immune system all within the same sample. Profile expression levels of 23 state markers, including checkpoints like PD-1, PD-L1, CTLA-4, LAG3, TIM-3, TIGIT, and ICOS across all CD8 and CD4 T cell subsets. Track the pharmacodynamics of the entire immune response with markers of immune activation across T, B, NK, DC, and Monocyte subsets, such as granzyme B, HLA-DR, CD27, CD28, KI67, and CD38. See the full picture of a patients’ immune response to treatment, from activation to effector function to exhaustion, and identify critical biomarkers of response and safety for your clinical programs! https://lnkd.in/erfy6AM8

#Araclon Biotech's Phase 2 trial of its #Alzheimer's vaccine, #ABvac40, shows promising results, potentially slowing disease progression by up to 38%. With a robust safety profile and no severe side effects reported... Dr. Jose Terencio, CEO of Araclon #Biotech and Vice President of #Grifols Innovation, stated that the results for ABvac40 confirm its clinical potential as an Alzheimer's treatment, noting: "We are pleased to report final positive results from the Phase 2 study of ABvac40, including a robust immune response with some significant reduction in disease progression, all with a favorable safety profile.'' #Alzheimersvaccine https://lnkd.in/dpTDezsA

Takeda has sealed a major $2.2 billion agreement with AC Immune to enhance and market AC Immune's Alzheimer’s vaccine candidate, ACI-24.060, now in early-stage clinical trials. The collaboration involves an upfront payment of $100 million to AC Immune, with additional milestone payments that could reach $2.1 billion, plus sales royalties. This substantial deal reflects confidence in the promising future of #Alzheimer's treatment and positions Takeda as a key player in pioneering treatments for this challenging disease. The substantial investment and the strategic nature of the partnership signal strong confidence in the potential of immunotherapy in Alzheimer’s disease, reflecting a growing trend of large-scale investments in neurodegenerative disease research. #leamanlifesciences https://lnkd.in/dbNmfdi6

Exciting News from Araclon Biotech, S.L. Biotech! 🔬 Their Phase II trial data analysis confirms the safety of the experimental Alzheimer’s disease vaccine, ABvac40. In a recent presentation at the 2023 Clinical Trials on Alzheimer’s Disease conference, they reported "encouraging" results in patients with mild cognitive impairment or early-stage AD. This active vaccine targets the Aβ40 peptide and has shown a favorable safety profile with a robust immune response. While not designed to test cognitive efficacy, the treated group displayed up to a 38% reduction in disease progression. This breakthrough could potentially alter the course of the disease. Araclon is now evaluating the next steps forward in this promising journey to combat Alzheimer’s. #AlzheimersResearch #MedicalBreakthroughs #AraclonBiotech #OBI4You https://lnkd.in/gK_UqJFJ

Want to know more about sickle cell disease and its detection? Discover now the origin of this disease, its consequences, and how to diagnose it efficiently with SYnAbs tools! #technology #lifescience #immunology #antibodies #medicine #cancer #innovation #gpcr #synabs #monoclonalantibodies #drugdiscovery #biotechnology #research #ionchannels #biologics #biotech #pharma #pharmaindustry #pharmaceuticals #oncology #healthcare #drugdevelopment #sicklecelldisease #sicklecell #diagnostics